Safety and Tolerability Study of Allogeneic Mesenchymal Stem Cell Infusion in Adults With Cystic Fibrosis

This will be a prospective, single-center, dose-escalation, open-label interventional study to evaluate the safety and tolerability of allogeneic human mesenchymal stem cells (hMSCs) in 15 clinically stable subjects with cystic fibrosis (CF) age ≥ 18 years. After a two to six week screening period, subjects will have a Baseline visit (Days 1-2) where they will undergo a single intravenous infusion of up to 5 x 10E6 allogeneic hMSCs/kilogram (hMSCs/kg) of body weight. Infusions will be performed in the Dahms Clinical Research Unit (DCRU) of University Hospitals Cleveland Medical Center. Subjects will be monitored for any infusion related toxicities for 24 hours after the infusion. Subsequent study visits will occur on Days 7, 14, 28, Months 3 and 6 and telephone calls will occur on Days 4 (or 5), 21, 56 and Month 12. Subject safety and tolerability of a single dose of hMSCs will be evaluated at study visits by review of subject diaries, interval history, pulmonary exacerbations, physical examination, spirometry, and analysis of safety laboratories. Special attention will be placed upon detecting pulmonary exacerbations because anti-inflammatory therapies theoretically could suppress the immune system to the point where it leads to increased infectious complications, although MSC therapeutics are proposed to be antimicrobial. In addition to evaluating safety, this study will also explore efficacy end-points for future clinical trials of MSCs in CF including inflammatory biomarkers from blood and sputum. Serum markers (calprotectin, myeloperoxidase (MPO), granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-1β (IL-1β), IL-6, IL8, IL-17, and tumor necrosis factor-a (TNF-a) and sputum markers (white cell counts and differentials, IL-1β, IL-6, IL-8, IL-10, IL-17, GM-CSF, macrophage inflammatory protein-3a (MIP- 3a), TNF-a, and active proteases including neutrophil elastase, alpha-1-antitrypsin, and matrix metallopeptidase 9 (MMP-9) will be determined at Baseline and on Days 7 and 28 for with-in subject comparison. All subject samples will be archived for future projects. Finally, a diagnostic bone marrow exam will be performed on subjects with CF who consent to undergo this optional procedure. Bone marrow samples will be banked and used for future translational studies.

Cystic Fibrosis (CF) Subject Inclusion Criteria:

• Male or female ≥18 years of age
• Confirmed diagnosis of CF as evidenced by 1 or more clinical features consistent with the CF phenotype and 1 or more of the following criteria:

• Sweat chloride equal to or greater than 60 milliequivalents per liter (mEq/L) by quantitative pilocarpine iontophoresis test (QPIT)
• 2 well-characterized, disease causing mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene
• Clinically stable with no significant changes in health status within 2 weeks prior to screening.
• Forced expiratory volume in the first second (FEV1) ≥ 40% predicted for age based on the global lung function initiative equations at the screening visit
• Weight ≥ 40 kilograms at the screening visit
• Able to perform repeatable, consistent efforts in pulmonary function testing
• Written informed consent obtained from the subject.

CF Subject Exclusion Criteria:

• Use of an investigational agent within the 4-week period prior to Visit 1 (Day -42 to -10)
• Chronic daily (>10 mg) or alternate daily (>20 mg on alternate days) use of systemic corticosteroids within the 4 weeks prior to Visit 1 (Day -42 to -10) or initiation of any dosage of systemic corticosteroids within 72 hours prior to Visit 2 (Day 1).
• Use of hydroxychloroquine or immunosuppressants.
• Initiation of a new antibiotic (oral, intravenous, and/or inhaled) that is not part of the subject's maintenance regimen for treatment of acute respiratory symptoms within 2 weeks prior to screening through Visit 2 (Day 1)
• Initiation of any new chronic therapy (e.g., Pulmozyme®, hypertonic saline, Kalydeco®, Orkambi®, high-dose ibuprofen azithromycin, TOBI®, Cayston®, nebulized colistiin, bronchodilators, inhaled corticosteroids, etc.) within 4 weeks prior to screening
• Active treatment for non-tuberculous Mycobacteria
• History of a sputum culture positive for a Burkholderia cepacia complex organism in the previous 12 months.
• Current tobacco smoker
• Oxygen saturation < 92% on room air at Visit 1 (Day -42 to -10)
• History of pulmonary hypertension
• Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2.5 times the upper limit of normal at screening, documented biliary cirrhosis, or portal hypertension
• Total bilirubin concentration > 1.2 milligram per deciliter (mg/dL) at screening
• Creatinine > 1.8 mg/dL at screening
• Pregnant, breastfeeding, or unwilling to practice birth control between Visit 2 (Day 1) and Telephone Call 3 (Day 56) (acceptable forms of contraception: abstinence, hormonal birth control, intrauterine device, or barrier method plus a spermicidal agent), unless surgically sterilized or postmenopausal
• Screening hematology with white blood cell count < 4.5 x 109 cells/liter, hematocrit < 30%, and platelets < 150 x 109 platelets/liter
• History of invasive cancer requiring systemic therapy
• History of organ transplantation
• Currently listed for lung transplantation or having potential to be listed for lung transplantation in the succeeding 12 calendar months from screening
• Subject unlikely to complete the study as determined by the Investigator

Inclusion criteria

for Healthy Volunteer Donors (NOTE: Enrollment for Healthy Volunteers is closed):

• Male/female age ≥ 18 years to ≤ 40 years
• Able to understand and sign consent form (a legally authorized representative will not be permitted)

Inclusion criteria

for CF Donors:

• CF subject enrolled in the main study and consented to this optional procedure

Exclusion criteria

for both Healthy Volunteer (HV) Donors and CF Donors:

• Fever or current illness on the day of the cell collection
• Evidence of communicable disease
• Any significant change in health status within 2 weeks prior to cell collection that the Principal Investigator/Sub-Investigator deems relevant to exclude participation
• Subject reported history of organ transplantation
• Subject reported history of human immunodeficiency virus, hepatitis B or C, or syphilis
• For HV donors only, subject-reported known history of being diagnosed with cystic fibrosis (CF) or being a CF carrier (one copy of CF gene mutation)
• Positive screening blood test result for any infectious disease.
• For HV donors only, positive test result for CMV or a CF gene mutation.
• Pregnant, planning a pregnancy, or breast-feeding at screening